Committee For Medicinal Products For Human Use Recommends Approval Of Indication Extension Of Johnson & Johnson's TALVEY To Treat Adults With Relapsed Or Refractory Multiple Myeloma

https://www.jnj.com/media-center/press-releases/chmp-recommends-approval-of-johnson-johnsons-talvey-talquetamab-plus-daratumumab-in-earlier-line-treatment-of-relapsed-refractory-multiple-myeloma